Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment...
June 01, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
May 09, 2023 16:15 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon...
May 01, 2023 16:01 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
April 25, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
March 27, 2023 16:15 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b)...
March 22, 2023 19:23 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
February 28, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
January 26, 2023 07:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights...
January 17, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...